Autoimmune hepatitis - update on clinical management in 2017
Standard
Autoimmune hepatitis - update on clinical management in 2017. / Liwinski, Timur; Schramm, Christoph.
In: CLIN RES HEPATOL GAS, Vol. 41, No. 6, 12.2017, p. 617-625.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autoimmune hepatitis - update on clinical management in 2017
AU - Liwinski, Timur
AU - Schramm, Christoph
N1 - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
PY - 2017/12
Y1 - 2017/12
N2 - Autoimmune hepatitis (AIH) is a progressive immune mediated liver disease of unknown origin. Key diagnostic features include hypergammaglobulinemia/elevated serum-IgG, characteristic circulating autoantibodies, periportal hepatitis with interface activity on liver biopsy and the exclusion of hepatotropic viruses. However, the diagnosis is challenging in cholestatic and severe presentations. It can be difficult to differentiate AIH from drug-induced liver injury. Although many patients initially respond to standard immunosuppressive therapy, a significant proportion experiences intolerable side effects or insufficient treatment response. This underlines the need for effective alternative treatment options, which are still very limited and based on rather poor evidence. This review summarises core aspects of the clinical management of AIH with focus on recent achievements and unmet needs.
AB - Autoimmune hepatitis (AIH) is a progressive immune mediated liver disease of unknown origin. Key diagnostic features include hypergammaglobulinemia/elevated serum-IgG, characteristic circulating autoantibodies, periportal hepatitis with interface activity on liver biopsy and the exclusion of hepatotropic viruses. However, the diagnosis is challenging in cholestatic and severe presentations. It can be difficult to differentiate AIH from drug-induced liver injury. Although many patients initially respond to standard immunosuppressive therapy, a significant proportion experiences intolerable side effects or insufficient treatment response. This underlines the need for effective alternative treatment options, which are still very limited and based on rather poor evidence. This review summarises core aspects of the clinical management of AIH with focus on recent achievements and unmet needs.
KW - Journal Article
KW - Review
U2 - 10.1016/j.clinre.2017.07.002
DO - 10.1016/j.clinre.2017.07.002
M3 - SCORING: Review article
C2 - 28882739
VL - 41
SP - 617
EP - 625
JO - CLIN RES HEPATOL GAS
JF - CLIN RES HEPATOL GAS
SN - 2210-7401
IS - 6
ER -